FAS and fatty liver disease: In the liver, activation of hepatic CB1R by endocannabinoids induces the expression of acetyl coenzyme-A carboxylase-1 (ACC1), fatty acid synthase (FAS) and sterol regulatory element-binding transcription factor 1 (SREBPF1), resulting in fatty acid synthesis and leading to hepatic steatosis [32], however, mice with hepatic CB1R deleted are protected from metabolic disorders such as dyslipidemia, hyperglycemia, insulin resistance and hepatic steatosis [32,34,102].